TWI633189B - Manufacturing method of fermented matured placenta solution - Google Patents

Manufacturing method of fermented matured placenta solution Download PDF

Info

Publication number
TWI633189B
TWI633189B TW104137012A TW104137012A TWI633189B TW I633189 B TWI633189 B TW I633189B TW 104137012 A TW104137012 A TW 104137012A TW 104137012 A TW104137012 A TW 104137012A TW I633189 B TWI633189 B TW I633189B
Authority
TW
Taiwan
Prior art keywords
fermented
placenta
matured
solution
aforementioned
Prior art date
Application number
TW104137012A
Other languages
Chinese (zh)
Other versions
TW201632627A (en
Inventor
三井幸雄
Original Assignee
荷魯斯股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷魯斯股份有限公司 filed Critical 荷魯斯股份有限公司
Publication of TW201632627A publication Critical patent/TW201632627A/en
Application granted granted Critical
Publication of TWI633189B publication Critical patent/TWI633189B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L13/00Meat products; Meat meal; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L13/00Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/20Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065Microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/982Reproductive organs; Embryos, Eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Abstract

本發明之課題係提供使胎盤溶液的吸收性或有用成分增加之發酵熟成胎盤溶液的製造方法。 An object of the present invention is to provide a method for producing a placenta solution which is fermented and cooked to increase the absorptivity or useful components of the placenta solution.

本發明之發酵熟成胎盤溶液的製造方法係在豬、羊或馬的胎盤溶液中,加入具有發酵作用之酵母菌而使胎盤發酵及熟成之發酵熟成胎盤溶液的製造方法,其特徵為將相對於胎盤溶液而言以重量比計6~15%的黑糖添加至胎盤溶液中並使其發酵,並在發酵後使其熟成。 The manufacturing method of the fermented and matured placenta solution of the present invention is a method for manufacturing fermented and matured placenta solution by adding fermenting yeast to placenta solution of pig, sheep or horse, which is characterized by For the placenta solution, 6 to 15% by weight of brown sugar is added to the placenta solution to ferment it, and it is matured after fermentation.

Description

發酵熟成胎盤溶液的製造方法 Manufacturing method of fermented matured placenta solution

本發明係關於利用為健康食品用原料或化妝品用原料之發酵熟成胎盤溶液的製造方法。 The present invention relates to a method for producing a placenta solution by fermentation and maturation as a raw material for health food or a raw material for cosmetics.

在萃取自屬於哺乳動物獨有的臟器之胎盤(placenta)的胎盤素中,係包含胺基酸或酵素類等各式各樣的有用成分。因此,胎盤素現正用作健康食品或化妝品之原料等,而在其中,特別是從安全性之方面而言,大多使用萃取自豬或羊、馬之胎盤的胎盤素。 Placenta extracted from placenta, which is a unique organ of mammals, contains various useful ingredients such as amino acids and enzymes. Therefore, placenta is currently used as a raw material for health foods or cosmetics, and among them, especially in terms of safety, placenta extracted from placenta of pigs, sheep, and horses is mostly used.

此處,在專利文獻1中,已提案一種含有豬的胎盤之健康食品的製造方法,其係將豬的胎盤以水分成為50%(重量)至80%(重量)之方式進行煮沸後,加入包含具有發酵作用之酵母菌及乳酸菌之發酵液,在發酵前或發酵途中加入葡萄糖並使其於20℃至35℃發酵24小時至72小時。 Here, in Patent Document 1, a method for producing a health food containing a pig's placenta has been proposed, which involves boiling a pig's placenta so that the moisture becomes 50% to 80% by weight and then adding Fermentation liquid containing yeast and lactic acid bacteria with fermentation function, glucose is added before fermentation or during fermentation and allowed to ferment at 20 ° C to 35 ° C for 24 hours to 72 hours.

〔先前技術文獻〕 [Previous Technical Literature] 〔專利文獻〕 [Patent Literature]

[專利文獻1]日本專利特開2005-185242號公報 [Patent Document 1] Japanese Patent Laid-Open No. 2005-185242

然而,在用作健康食品或化妝品等之原料之情況,係期望使胎盤溶液的吸收性或有用成分盡可能地增加,但如專利文獻1所記載之發明般,僅在煮沸後使其發酵24小時至72小時,就使胎盤溶液的吸收性或有用成分增加而言並不充分。 However, when used as a raw material for health foods, cosmetics, etc., it is desirable to increase the absorptiveness or useful components of the placenta solution as much as possible. However, as in the invention described in Patent Document 1, it is fermented only after boiling 24 Hours to 72 hours are insufficient to increase the absorptiveness or useful ingredients of the placenta solution.

於是,本發明之目的係提供使胎盤溶液的吸收性或有用成分增加之發酵熟成胎盤溶液的製造方法。 Accordingly, an object of the present invention is to provide a method for producing a placenta solution by fermentation and maturation, which increases the absorptivity or useful components of the placenta solution.

請求項1所記載之本發明之發酵熟成胎盤溶液的製造方法,係在豬、羊或馬的胎盤溶液中,加入具有發酵作用之酵母菌而使胎盤發酵及熟成之發酵熟成胎盤溶液的製造方法,其特徵為將相對於胎盤溶液而言以重量比計6~15%的黑糖添加至胎盤溶液中並使其發酵,並在發酵後使其熟成。 The method for producing a fermented and matured placenta solution according to the present invention described in claim 1, is a method for producing a fermented and matured placenta solution by adding a yeast having a fermenting effect to a placental solution of a pig, a sheep, or a horse. It is characterized by adding 6 to 15% of brown sugar to the placenta solution in a weight ratio to the placenta solution and fermenting it, and ripening it after fermentation.

請求項2所記載之本發明,其特徵為在請求項1所記載之發酵熟成胎盤溶液的製造方法中,具有下列步驟:將黑糖添加至胎盤溶液中之黑糖添加步驟;在黑糖添加步驟之後,於80~100℃的溫度中進行20分鐘~60分鐘加熱殺菌之殺菌步驟;在殺菌步驟之後,強制冷卻至35℃以 下的溫度之冷卻步驟;在冷卻步驟之後,加入酵母菌並於20℃~35℃的溫度中使其發酵1個月之發酵步驟;以及在發酵步驟之後,於20℃~25℃的溫度中使其熟成2個月之熟成步驟。 The invention according to claim 2 is characterized in that, in the method for producing a fermented and matured placenta solution according to claim 1, the method has the following steps: a brown sugar adding step of adding brown sugar to the placental solution; and after the brown sugar adding step, The heat sterilization step is performed at a temperature of 80 to 100 ° C for 20 minutes to 60 minutes; after the sterilization step, it is forced to cool to 35 ° C to A cooling step at a lower temperature; a fermentation step in which yeast is added and fermented at a temperature of 20 ° C to 35 ° C for one month after the cooling step; and a temperature of 20 ° C to 25 ° C after the fermentation step Let it mature for 2 months.

請求項3所記載之本發明,其特徵為在請求項2所記載之發酵熟成胎盤溶液的製造方法中,在熟成結束後所測定之S-腺苷甲硫胺酸(SAMe)及超活性胺基酸(SA胺基酸)的濃度係將相對於胎盤溶液而言以重量比計10%的蔗糖代替黑糖添加至胎盤溶液中並施行殺菌步驟至熟成步驟所產生之SAMe及SA胺基酸的濃度以上。 The invention according to claim 3 is characterized in that, in the method for producing a fermented and matured placenta solution according to claim 2, the S-adenosylmethionine (SAMe) and the super active amine measured after the completion of ripening Concentration of SA amino acid (SA amino acid) is the concentration of SAMe and SA amino acid produced in the placenta solution by adding 10% by weight of sucrose in place of brown sugar to the placenta solution and performing the sterilization step to the maturation step. Above the concentration.

請求項4所記載之本發明,其特徵為在請求項2所記載之發酵熟成胎盤溶液的製造方法中,在熟成結束後所測定之SAMe及SA胺基酸的濃度係將相對於胎盤溶液而言以重量比計10%的葡萄糖代替黑糖添加至胎盤溶液中並施行殺菌步驟至熟成步驟所產生之SAMe及SA胺基酸的濃度以上。 The invention according to claim 4 is characterized in that, in the method for producing a fermented and matured placenta solution according to claim 2, the concentrations of SAMe and SA amino acids measured after the maturation are compared with the placental solution In other words, 10% of glucose is added to the placenta solution instead of brown sugar in a weight ratio, and the sterilization step is performed until the concentrations of SAMe and SA amino acids produced by the maturation step are above.

請求項5所記載之本發明,其特徵為在請求項2至請求項4中任一項所記載之發酵熟成胎盤溶液的製造方法中,在熟成步驟之後的固形份中所計測之分子量分佈係就未滿200而言為10~20%、就1000~3000而言為30~40%、就3000~6000而言為20~25%。 The invention described in claim 5 is characterized in that, in the method for producing a fermented and matured placenta solution according to any one of claim 2 to claim 4, the molecular weight distribution measured in the solid content after the ripening step is 10 to 20% for less than 200, 30 to 40% for 1000 to 3000, and 20 to 25% for 3000 to 6000.

請求項6所記載之本發明,其特徵為在請求項2至請求項4中任一項所記載之發酵熟成胎盤溶液的製造方法中,在熟成步驟之後的固形份中,係包含丙胺酸10莫耳 %以上、胱胺酸0.4莫耳%以上。 The invention described in claim 6 is characterized in that, in the method for producing a fermented matured placenta solution according to any one of claim 2 to claim 4, the solid content after the ripening step contains alanine 10 Mol % Or more, 0.4 mole or more of cystine.

請求項7所記載之本發明,其特徵為在請求項2至請求項4中任一項所記載之發酵熟成胎盤溶液的製造方法中,在熟成步驟之後的固形份中,係包含鈉300mg/100g以上、鈣100mg/100g以上、鎂15mg/100g以上、菸鹼酸2mg/100g以上、鋅2mg/100g以上。 The invention according to claim 7 is characterized in that, in the method for producing a fermented and matured placenta solution according to any one of claims 2 to 4, the solid content after the ripening step contains 300 mg of sodium / 100 g or more, 100 mg / 100 g or more of calcium, 15 mg / 100 g or more of magnesium, 2 mg / 100 g or more of nicotinic acid, and 2 mg / 100 g or more of zinc.

根據本發明,可獲得可使吸收性增高並使有用成分增加,且經由摻合於化妝品中而提升保濕力,經由摻合於健康食品中而成為溫和的味道之胎盤素。 According to the present invention, it is possible to obtain a placenta which can increase the absorbency and increase the useful ingredients, enhance the moisturizing power by blending in cosmetics, and blend into healthy foods to give a mild flavor.

圖1係顯示SA胺基酸之活性氧去除作用之圖。 Figure 1 is a graph showing the active oxygen removal effect of SA amino acid.

圖2係顯示SA胺基酸之過氧化脂質的抑制作用之圖。 Fig. 2 is a graph showing the inhibitory effect of lipid peroxides of SA amino acids.

圖3係顯示塗佈摻合SA胺基酸之化妝品後之肌膚的角質水分量之推移之圖。 FIG. 3 is a graph showing the transition of the horny moisture content of the skin after applying a cosmetic containing SA amino acid.

圖4係顯示塗佈摻合SA胺基酸之化妝品後之肌膚的經表皮水分蒸散量之推移之圖。 FIG. 4 is a graph showing the transepidermal moisture evapotranspiration of the skin after the application of cosmetics containing SA amino acid.

圖5係顯示SA胺基酸之MMP-1活性抑制作用之圖。 Figure 5 is a graph showing the inhibitory effect of SA amino acid on MMP-1 activity.

圖6係對添加相對於胎盤溶液而言以重量比計3%、 6%、10%、15%的黑糖,在熟成結束後所測定之SAMe及SA胺基酸的產生進行比較之圖。 Fig. 6 shows the addition of 3% by weight relative to the placenta solution. 6%, 10%, 15% of brown sugar, compared to SAMe and SA amino acid production measured after the maturation is compared with the graph.

圖7係顯示在使黑糖對胎盤溶液之添加時機不同之實驗中,在熟成結束後所測定之SAMe產生及SA胺基酸產生之結果之圖。 FIG. 7 is a graph showing the results of SAMe production and SA amino acid measurement after the maturation is completed in experiments in which brown sugar was added to the placenta solution at different timings.

圖8係顯示在使發酵期不同之實驗中,SAMe產生及SA胺基酸產生之測定結果之圖。 Fig. 8 is a graph showing the measurement results of SAMe production and SA amino acid production in experiments in which fermentation periods are different.

圖9係顯示在使熟成期不同之實驗中,SAMe產生及SA胺基酸產生之測定結果之圖。 FIG. 9 is a graph showing the measurement results of SAMe production and SA amino acid production in experiments in which the maturation period is different.

圖10係顯示依據本發明之一實施例之發酵熟成胎盤之分子量分佈之圖。 FIG. 10 is a graph showing a molecular weight distribution of a fermented mature placenta according to an embodiment of the present invention.

圖11係顯示相同發酵熟成胎盤之成分之圖。 FIG. 11 is a diagram showing the components of the placenta fermented by the same fermentation.

圖12係顯示相同發酵熟成胎盤之礦物質/維生素含量之圖。 Figure 12 is a graph showing the mineral / vitamin content of the placenta fermented by the same fermentation.

依據本發明之第1實施形態之發酵熟成胎盤溶液的製造方法係將相對於胎盤溶液而言以重量比計6~15%的黑糖添加至胎盤溶液中並使其發酵,並在發酵後使其熟成。根據本實施形態,可獲得可使吸收性增高並使有用成分增加,且經由摻合於化妝品中而提升保濕力,經由摻合於健康食品中而成為溫和的味道之胎盤。 The method for producing a fermented and matured placenta solution according to the first embodiment of the present invention is to add 6 to 15% by weight of brown sugar to the placenta solution to the placenta solution to ferment it, and then ferment it. ripe. According to this embodiment, a placenta can be obtained which can increase the absorbency and increase the useful ingredients, enhance the moisturizing power by blending in cosmetics, and blend into healthy food to give a mild taste.

本發明之第2實施形態係在依據第1實施形態之發酵熟成胎盤溶液的製造方法中,具有下列步驟:將 黑糖添加至胎盤溶液中之黑糖添加步驟;在黑糖添加步驟之後,於80~100℃的溫度中進行20分鐘~60分鐘加熱殺菌之殺菌步驟;在殺菌步驟之後,強制冷卻至35℃以下的溫度之冷卻步驟;在冷卻步驟之後,加入酵母菌並於20℃~35℃的溫度中使其發酵1個月之發酵步驟;以及在發酵步驟之後,於20℃~25℃的溫度中使其熟成2個月之熟成步驟。根據本實施形態,可特別提高SAMe及SA胺基酸的濃度。 The second embodiment of the present invention has the following steps in the method for producing a fermented and matured placenta solution according to the first embodiment: Brown sugar added to the placenta solution. Brown sugar added step. After the brown sugar added step, heat-sterilize the sterilization step at a temperature of 80 to 100 ° C for 20 minutes to 60 minutes. Cooling step; after the cooling step, adding yeast and fermenting at a temperature of 20 ° C to 35 ° C for 1 month; and after the fermentation step, ripening at a temperature of 20 ° C to 25 ° C 2 months ripening step. According to this embodiment, the concentrations of SAMe and SA amino acids can be particularly increased.

此處,SAMe係指S-腺苷甲硫胺酸(S-adenosylmethionine),SA胺基酸係指超活性胺基酸(super active amino acid)。 Here, SAMe means S-adenosylmethionine, and SA amino acid means super active amino acid.

SAMe(S-腺苷甲硫胺酸)係於1974年歐洲在世界上最初被開發為憂鬱症之治療藥。此外,在美國係作為對關節炎特別有效果之補充品而受到歡迎,除了關節炎以外,亦被認為對憂鬱症、肝疾患有效果。特定而言,關節症的患者係呈逐年增加之傾向,支撐關節之健康食品等的需求係逐漸提高。 SAMe (S-adenosylmethionine) was first developed in Europe in 1974 as a treatment for depression. In addition, it is popular in the United States as a supplement that is particularly effective for arthritis. In addition to arthritis, it is also considered to have effects on depression and liver disease. In particular, the number of patients with arthrosis tends to increase year by year, and the demand for healthy foods and the like that support joints is gradually increasing.

此外,SA胺基酸(超活性胺基酸)係具有3項作用之胺基酸。 In addition, SA amino acid (super active amino acid) is an amino acid having three functions.

第1項為活性氧抑制效果。由於活性氧係構造上不安定,因而會與皮膚的DNA或脂質、蛋白質結合而引起細胞傷害,成為皮膚老化之一項原因。 The first term is the active oxygen inhibitory effect. Because the structure of the active oxygen system is unstable, it can bind to the skin's DNA, lipids, and proteins and cause cell damage, which becomes a cause of skin aging.

圖1係藉由測定利用次黃嘌呤-黃嘌呤氧化酶系統使O2 -生成,並使SA胺基酸共存時之O2 -生成量,而顯示出 SA胺基酸之活性氧去除作用。O2 -係使用作為顯色試藥之硝基藍四唑鎓(nitroblue tetrazolium)進行檢測。此處,SA胺基酸係顯示出濃度依存性地消去O2 -FIG. 1 shows the active oxygen removal effect of SA amino acid by measuring the amount of O 2 - generated when hypoxanthine-xanthine oxidase system is used to generate O 2 - and co-exist SA amino acid. O 2 - is detected using nitroblue tetrazolium as a color development reagent. Here, SA shows the concentration dependence of the amino acid-based erased O 2 -.

此外,圖2係顯示SA胺基酸對於以使用阿脲(alloxan)而化學性產生之O2 -作為起始劑之脂質過氧化反應的抑制作用之圖。另外,已知阿脲會化學性生成O2 -,並給予氧化壓力。此處,SA胺基酸相較於其他抗氧化劑而言係顯示出顯著地抑制脂質的氧化。 In addition, FIG. 2 is a graph showing the inhibitory effect of SA amino acid on lipid peroxidation reaction chemically produced by using O 2 -which is alloxan as a starter. In addition, urea is known to chemically generate O 2 - and to give oxidative stress. Here, SA amino acids have been shown to significantly inhibit lipid oxidation compared to other antioxidants.

第2項為保濕效果。圖3、4係顯示以角質水分量呈現低值,並有肌膚粗糙/乾燥等自覺之40~60歲的成人女性7名(平均年齡47.1歲)為對象,實施開放性試驗之結果,圖3係顯示塗佈摻合SA胺基酸之化妝品後之肌膚的角質水分量〔μS〕之推移之圖,圖4係顯示塗佈摻合SA胺基酸之化妝品後之肌膚的經表皮水分蒸散量〔g/m2.h〕之推移之圖。將試驗期設為8週,在早晚2次每次洗淨後適量塗佈含有SA胺基酸之製品。在試驗開始日及自試驗開始起4、8週後測定肌膚的角質水分量及經表皮水分蒸散量,並施行評估。此處,藉由8週的連用,角質水分量在含有SA胺基酸之製品連用部位,係明顯地上升。此可視為角質的水分保持機能本身獲得改善之結果。針對經表皮水分蒸散量,亦可看出降低之傾向,並可認出乾燥狀態的改善。 The second item is the moisturizing effect. Figures 3 and 4 show the results of an open test with 7 adult females (average age 47.1 years) of 40-60 years old with low horny moisture content and conscious skin roughness / dryness, etc., Figure 3 Fig. 4 is a graph showing the transition of keratin moisture [μS] of the skin after applying the SA amino acid-containing cosmetic, and Fig. 4 shows the transepidermal moisture evapotranspiration of the skin after applying the SA amino acid-containing cosmetic [G / m 2 . h] transition diagram. The test period was set to 8 weeks, and a product containing SA amino acid was applied in an appropriate amount after washing twice in the morning and evening. The horny moisture content and transepidermal water evapotranspiration of the skin were measured on the test start day and 4 or 8 weeks after the start of the test, and evaluated. Here, after 8 weeks of continuous use, the horny moisture content increased significantly at the site where the product containing SA amino acid was used. This can be regarded as a result of the improvement of the horny moisture retention function itself. Regarding the transepidermal moisture evapotranspiration, the tendency to decrease can also be seen, and the improvement of the dry state can be recognized.

第3項為膠原蛋白產生效果。作為分解I型膠原蛋白之酵素之MMP-1係藉由暴露於UVA(紫外線A波)而活 化。圖5係為了評估SA胺基酸之MMP-1活性阻礙,而實際驗證藉由UVA所亢進之MMP-1的活性是否會受到SA胺基酸所抑制之結果。對於正常人類纖維母細胞,使各種濃度的SA胺基酸共存並照射UVA,在24小時後回收培養基,並測定其MMP-1活性。由此,SA胺基酸係顯示出濃度依存性地抑制MMP-1的活性。 The third item is the collagen production effect. MMP-1, which is an enzyme that breaks down type I collagen, is activated by exposure to UVA (ultraviolet A wave). Into. Fig. 5 is a result of actually verifying whether the activity of MMP-1 which is enhanced by UVA is inhibited by SA amino acid in order to evaluate the inhibition of MMP-1 activity of SA amino acid. For normal human fibroblasts, SA amino acids of various concentrations were co-existed and irradiated with UVA. After 24 hours, the culture medium was recovered and its MMP-1 activity was measured. Thus, the SA amino acid system showed a concentration-dependent inhibition of MMP-1 activity.

根據依據本實施形態之發酵熟成胎盤溶液的製造方法,可獲得在熟成結束後所測定之SAMe及SA胺基酸的濃度係將相對於胎盤溶液而言以重量比計10%的蔗糖代替黑糖添加至胎盤溶液中並施行殺菌步驟至熟成步驟所產生之SAMe及SA胺基酸的濃度以上之胎盤溶液。 According to the method for producing a fermented and matured placenta solution according to this embodiment, it is possible to obtain the concentrations of SAMe and SA amino acids measured after the maturation is completed. The sucrose is added to the placental solution at a weight ratio of 10% in place of brown sugar. Placenta solution into the placenta solution and perform the sterilization step to a concentration of SAMe and SA amino acids above the concentration in the maturation step.

根據依據本實施形態之發酵熟成胎盤溶液的製造方法,可獲得在熟成結束後所測定之SAMe及SA胺基酸的濃度係將相對於胎盤溶液而言以重量比計10%的葡萄糖代替黑糖添加至胎盤溶液中並施行殺菌步驟至熟成步驟所產生之SAMe及SA胺基酸的濃度以上之胎盤溶液。 According to the method for producing a fermented and matured placenta solution according to this embodiment, it is possible to obtain the concentrations of SAMe and SA amino acids measured after the maturation are completed. 10% by weight of glucose is added to the placenta solution instead of brown sugar. Placenta solution into the placenta solution and perform the sterilization step to a concentration of SAMe and SA amino acids above the concentration in the maturation step.

根據依據本實施形態之發酵熟成胎盤溶液的製造方法,可獲得在熟成步驟之後的固形份中所計測之分子量分佈係就未滿200而言為10~20%、就1000~3000而言為30~40%、就3000~6000而言為20~25%之胎盤溶液,藉由平衡良好地摻合各式各樣分子量的胺基酸或胜肽,可提高保濕效果。 According to the method for producing a fermented and matured placenta solution according to this embodiment, the molecular weight distribution measured in the solid content after the ripening step is 10 to 20% for less than 200 and 30 for 1,000 to 3000. The placenta solution of ~ 40% and 20 ~ 25% in terms of 3000 ~ 6000 can improve the moisturizing effect by blending amino acids or peptides of various molecular weights in a well-balanced manner.

根據依據本實施形態之發酵熟成胎盤溶液的製造方法,在熟成步驟之後的固形份中,係包含丙胺酸 10莫耳%以上、胱胺酸0.4莫耳%以上。 According to the method for producing a fermented and matured placenta solution according to this embodiment, the solid content after the ripening step contains alanine More than 10 mole% and 0.4 mole% cystine.

丙胺酸及胱胺酸係會對人體給予有效影響之胺基酸之一。丙胺酸係大量包含在蜆或蛤等貝類中之胺基酸,除了肝機能的改善以外,尚作為使免疫機能提升之胺基酸而包含在許多健康食品中。胱胺酸係2分子半胱胺酸鍵結而成之胺基酸,其係作為構成稱為角蛋白的蛋白質之胺基酸而大量含在毛髮或指甲中。就美白效果而言,由於其具有抑制會生成黑色的黑色素之酪胺酸酶的活性之作用,因而係大量摻合於化妝品等中。 Alanine and cystine are one of the amino acids that can effectively affect the human body. Alanine is a large amount of amino acids contained in shellfish such as cockles and clams. In addition to improving liver function, it is also included in many health foods as an amino acid that improves immune function. Cysteine is an amino acid composed of two molecules of cysteine, and it is contained in a large amount in hair or nails as an amino acid constituting a protein called keratin. In terms of whitening effect, it is incorporated in cosmetics and the like in large quantities because it has an effect of inhibiting tyrosinase activity that produces black melanin.

根據依據本實施形態之發酵熟成胎盤溶液的製造方法,在熟成步驟之後的固形份中,係包含鈉300mg/100g以上、鈣100mg/100g以上、鎂15mg/100g以上、菸鹼酸2mg/100g以上、鋅2mg/100g以上。 According to the method for producing a fermented and matured placenta solution according to this embodiment, the solid content after the ripening step includes 300 mg / 100 g or more of sodium, 100 mg / 100 g or more of calcium, 15 mg / 100 g or more of magnesium, and 2 mg / 100 g or more of nicotinic acid. , Zinc 2mg / 100g or more.

此等礦物質近年來係呈攝取量降低之傾向。舉例而言,鉀係呈現出在飲食攝取基準2015年版中所設定之成人攝取目標之約1~2成左右強係不足之問卷調查結果。特定而言,鋅在20~60世代中之不足係顯著,若基於飲食攝取基準所設定之建議量進行比較,則男女皆低於約1成。鎂係15歲以上的年齡層不夠充足,在20世代中可謂近3成係不足。由於此等礦物質之不足,除了女性的低體重化或骨質疏鬆症以外,尚有糖尿病的感染風險亦提高之傾向。因此,礦物質的攝取對於現代人而言可謂重大課題之一。 These minerals have tended to decrease in intake in recent years. For example, the potassium system shows the results of a questionnaire survey of about 10% to 20% of the adult intake target set in the 2015 edition of the dietary intake standard. In particular, the deficiency of zinc in the 20 to 60 generations is significant. If the recommended amount is set based on the dietary intake standard, it is less than about 10% for both men and women. The age group of 15 years and older is not enough, and in the 20th generation, nearly 30% of the system is insufficient. Due to the lack of these minerals, in addition to women's low body weight or osteoporosis, there is also a tendency for the risk of diabetes to increase. Therefore, the intake of minerals is one of the major issues for modern people.

〔實施例〕 [Example]

以下係針對依據本發明之一實施例之發酵熟成胎盤溶液的製造方法進行說明。 The following is a description of a method for manufacturing a fermented and matured placenta solution according to an embodiment of the present invention.

依據本實施例之發酵熟成胎盤溶液係具有下列步驟:將黑糖添加至胎盤溶液中之黑糖添加步驟;在黑糖添加步驟之後,於80~100℃的溫度中進行20分鐘~60分鐘加熱殺菌之殺菌步驟;在殺菌步驟之後,強制冷卻至35℃以下的溫度之冷卻步驟;在冷卻步驟之後,加入酵母菌並於20℃~35℃的溫度中使其發酵1個月之發酵步驟;以及在發酵步驟之後,於20℃~25℃的溫度中使其熟成2個月之熟成步驟。 The fermented and matured placenta solution according to this embodiment has the following steps: a brown sugar adding step of adding brown sugar to the placenta solution; and after the brown sugar adding step, heating and sterilizing at a temperature of 80 to 100 ° C. for 20 minutes to 60 minutes Step; after the sterilization step, a cooling step of forcibly cooling to a temperature below 35 ° C; after the cooling step, adding yeast and fermenting it at a temperature of 20 ° C to 35 ° C for 1 month; and fermentation After the step, it is aged at a temperature of 20 ° C to 25 ° C for 2 months.

胎盤素粉末係自豬、羊或馬的胎盤(placenta)去除皮膜組織,將絨毛組織切碎,以凍結酵素萃取法萃取出萃取物,並自此萃取物進一步去除雜質而成者,相對於胎盤而言以重量%計係8%左右。 Placenta powder is obtained from placenta of pigs, sheep or horses by removing the membrane tissue, chopping the villi tissue, extracting the extract by the frozen enzyme extraction method, and further removing impurities from the extract. Compared with the placenta, In terms of weight%, it is about 8%.

此外,在具有發酵作用之酵母菌中,可使用例如酵母菌(Saccharomyces)屬、念珠菌(Candida)屬、圓酵母菌(Torulopsis)屬、接合酵母菌(Zygosaccharomyces)屬、裂殖酵母菌(Schizosaccharomyces)屬、畢赤酵母菌(Pichia)屬、漢遜酵母菌(Hansenula)屬、克魯維酵母菌(Kluyveromyces)屬、德巴利酵母菌(Debaryomyces)屬。 In addition, among yeasts having a fermentation effect, for example, Saccharomyces, Candida, Torulopsis, Zygosaccharomyces, Schizosaccharomyces can be used. ) Genus, Pichia genus, Hansenula genus, Kluyveromyces genus, Debaryomyces genus.

在黑糖添加步驟中所添加之黑糖係設為相對於胎盤溶液而言以重量比計6~15%,更佳為6~10%。 The brown sugar added in the brown sugar addition step is set to 6 to 15% by weight relative to the placenta solution, and more preferably 6 to 10%.

圖6係添加相對於胎盤溶液而言以重量比計3%(實施例1)、6%(實施例2)、10%(實施例3)、15%(實施例4)的黑糖,測定在熟成結束後所測定之SAMe及SA胺基酸的產生,將產生最多者設為100並進行比較而得者。作為比較例,係使用相對於胎盤溶液而言以重量比計10%的蔗糖(比較例1)、及10%的葡萄糖(比較例2)。 Fig. 6 shows the addition of 3% (Example 1), 6% (Example 2), 10% (Example 3), and 15% (Example 4) brown sugars by weight ratio to the placenta solution. The production of SAMe and SA amino acids measured after the completion of ripening was set to 100 and compared with each other. As a comparative example, 10% of sucrose (Comparative Example 1) and 10% of glucose (Comparative Example 2) in terms of weight ratio to the placental solution were used.

就SAMe的產生而言,6~15%的黑糖係達10%的蔗糖以上,6~10%的黑糖係高於10%的蔗糖、及10%的葡萄糖。 As far as the production of SAMe is concerned, 6 to 15% of the brown sugars are more than 10% of sucrose, 6 to 10% of the brown sugars are higher than 10% of sucrose, and 10% of glucose.

就SA胺基酸的產生而言,3~15%的黑糖係高於10%的蔗糖、及10%的葡萄糖,但特定而言,6~10%的黑糖係達較高濃度。 In terms of the production of SA amino acids, 3 to 15% of the brown sugars are higher than 10% of sucrose and 10% of glucose, but specifically, 6 to 10% of the brown sugars have a higher concentration.

其次,針對黑糖之添加時機進行說明。 Next, the timing of adding brown sugar will be described.

圖7係對在發酵開始時添加100%(總量)、在發酵開始時添加80%並在發酵途中添加20%、在發酵開始時添加50%並在發酵途中添加50%、在發酵開始時添加80%並在熟成開始時添加20%、在發酵開始時添加50%並在熟成開始時添加50%之情況之SAMe及SA胺基酸的產生進行比較之實驗結果。 Figure 7 shows the addition of 100% (total) at the beginning of fermentation, 80% at the beginning of fermentation and 20% during the fermentation, 50% at the beginning of fermentation and 50% during the fermentation, and The results of comparison of the production of SAMe and SA amino acids in the case where 80% was added and 20% was added at the beginning of ripening, 50% was added at the beginning of fermentation and 50% was added at the beginning of ripening.

添加相對於胎盤溶液而言以重量比計6%的黑糖,並將總量設為100而進行表示。在熟成結束後所測定之SAMe及SA胺基酸的濃度,除了在發酵開始時以外另在發酵途中或熟成開始時添加一部分之情況係全部低於僅在 發酵開始時進行添加之情況。 Brown sugar was added at 6% by weight to the placenta solution, and the total amount was expressed as 100. The concentrations of SAMe and SA amino acids measured after the end of maturity are all lower than those that are only added during the fermentation or at the beginning of maturation, except at the beginning of fermentation. When adding at the start of fermentation.

從而,在著眼於SAMe及SA胺基酸之情況,黑糖較佳係僅在發酵開始時進行添加。 Therefore, when focusing on the SAMe and SA amino acids, it is preferred that the brown sugar is added only at the start of fermentation.

在黑糖添加步驟之後進行加熱殺菌。加熱殺菌後,係例如在60分鐘以內,使用冷水循環裝置,冷卻至35℃以下,較佳為25℃。若在糖與胺基酸共存之狀態下過度加熱,則因糖與胺基酸會進行結合、或該等之構造會發生變化,而使得發酵熟成之效果降低,熟成後之胎盤溶液會發生變色,並對氣味造成影響。 After the brown sugar addition step, heat sterilization is performed. After heat sterilization, the temperature is cooled to 35 ° C or lower, preferably 25 ° C, using a cold water circulation device within 60 minutes, for example. If the sugar and amino acid coexist in the state of excessive heating, the sugar and amino acid will be combined or the structure of these will be changed, which will reduce the effect of fermentation and maturation, and the placental solution will be discolored after maturation. And affect the smell.

其次,針對發酵步驟進行說明。 Next, a fermentation process is demonstrated.

圖8係對使發酵期不同之情況之SAMe及SA胺基酸的產生進行比較之實驗結果。測定在熟成結束後所測定之SAMe及SA胺基酸的產生,將產生最多者設為100並進行比較。另外,發酵溫度只要是20℃~35℃即可,而在本實驗中係於25℃進行發酵。 FIG. 8 is an experimental result comparing the production of SAMe and SA amino acids in the case of different fermentation periods. The production of SAMe and SA amino acids measured after the completion of the ripening was measured, and the largest amount was set to 100 and compared. In addition, as long as the fermentation temperature is 20 ° C to 35 ° C, fermentation is performed at 25 ° C in this experiment.

如圖8所示,相對於0.5個月而言,在1個月時SAMe及SA胺基酸的產生係增加,但在1.5個月時SAMe及SA胺基酸的產生係減少。 As shown in FIG. 8, with respect to 0.5 month, the production system of SAMe and SA amino acid increased at 1 month, but the production system of SAMe and SA amino acid decreased at 1.5 month.

從而,胎盤溶液之發酵期較佳係設為1個月。 Therefore, the fermentation period of the placenta solution is preferably set to one month.

其次,針對熟成步驟進行說明。 Next, the maturation step will be described.

圖9係對使熟成期不同之情況之SAMe及SA胺基酸的產生進行比較之實驗結果。測定在熟成結束後所測定之SAMe及SA胺基酸的產生,將產生最多者設為100並進行比較。另外,熟成溫度只要是20℃~25℃即可,而在 本實驗中係於25℃進行熟成。發酵期係設為1個月。 Fig. 9 shows the results of experiments comparing the production of SAMe and SA amino acids in cases where the maturation periods are different. The production of SAMe and SA amino acids measured after the completion of the ripening was measured, and the largest amount was set to 100 and compared. In addition, the ripening temperature is only required to be 20 ° C to 25 ° C. In this experiment, ripening was performed at 25 ° C. The fermentation period was set to 1 month.

如圖9所示,相對於1.5個月而言,在2個月時SAMe及SA胺基酸的產生係增加,但在2.5個月時SAMe及SA胺基酸的產生係減少。 As shown in FIG. 9, with respect to 1.5 months, the production systems of SAMe and SA amino acids increased at 2 months, but the production systems of SAMe and SA amino acids decreased at 2.5 months.

圖10係顯示依據本實施例之發酵熟成胎盤溶液的固形份之分子量分佈。將未經發酵熟成之胎盤溶液的固形份作為比較例。 FIG. 10 shows the molecular weight distribution of the solid content of the fermented and matured placenta solution according to this embodiment. The solid content of the placenta solution which was not fermented and matured was made into the comparative example.

依據本實施例之發酵熟成胎盤溶液係使用相對於胎盤溶液而言以重量比計6%的黑糖而得者。此外,自經發酵熟成之胎盤溶液(胎盤素)去除水分而獲得粉末狀的固形份(胎盤素末)。 The fermented and matured placenta solution according to this embodiment is obtained by using 6% brown sugar in a weight ratio with respect to the placenta solution. Further, the powdery solid content (placenta powder) was obtained by removing water from the fermented placenta solution (placenta).

在熟成步驟之後所計測之分子量分佈,在依據本實施例之發酵熟成胎盤溶液的固形份中,若與未經發酵熟成之胎盤溶液的固形份進行比較,則於未滿200、1000~3000、3000~6000可見到明確的差異,就未滿200而言達10~20%、就1000~3000而言達30~40%、就3000~6000而言達20~25%。 The molecular weight distribution measured after the maturation step, in the solid content of the fermented and matured placental solution according to this example, is compared with the solid content of the unfermented and matured placental solution at less than 200, 1000 ~ 3000, A clear difference can be seen from 3000 to 6000, 10 to 20% for less than 200, 30 to 40% for 1000 to 3000, and 20 to 25% for 3000 to 6000.

圖11係顯示依據本實施例之發酵熟成胎盤溶液的固形份之成分。將未經發酵熟成之胎盤溶液的固形份作為比較例。 FIG. 11 shows the components of the solid content of the fermented and matured placenta solution according to this embodiment. The solid content of the placenta solution which was not fermented and matured was made into the comparative example.

在熟成步驟之後所計測之成分,在依據本實施例之發酵熟成胎盤溶液的固形份中,若與未經發酵熟成之胎盤溶液的固形份進行比較,則特定而言,丙胺酸及胱胺酸係大幅增加,包含丙胺酸10莫耳%以上、胱胺酸0.4莫耳%以 上。 If the components measured after the maturation step are compared with the solid content of the fermented and matured placenta solution according to this example, compared with the solid content of the unfermented and matured placental solution, alanine and cystine The system has increased significantly, including more than 10 mole% of alanine and 0.4 mole% of cystine on.

此外,除此以外,以屬於必需胺基酸之離胺酸、組胺酸、纈胺酸、蘇胺酸、色胺酸為首,麩胺酸、絲胺酸、天冬醯胺、天冬胺酸等胺基酸在熟成步驟後係呈增加之傾向。 In addition, it includes lysine, histidine, valine, threonine, and tryptophan, which are essential amino acids, and glutamic acid, serine, asparagine, and asparagine. Amino acids such as acids tend to increase after the maturation step.

離胺酸係除了提高肝機能以外,尚作為抗體或激素、酵素等素材修復身體之組織。組胺酸係作用於關節,對慢性關節風濕症等之預防/改善發揮效果。纈胺酸係除了改善肝機能以外,尚增強身體之肌肉或恢復疲勞。此外,蘇胺酸亦會改善肝機能,並作為促進成長之營養素而發揮功能。色胺酸係作為腦內神經傳導物質,而具有使精神機能安定之效果。麩胺酸係大量包含在肝臟或豬肉中,藉由迅速地被身體所吸收而作為能量源。絲胺酸係包含在大豆等中,具有抑制肌膚的老化之效果。此外,天冬醯胺及天冬胺酸係除了將屬於有害物質之氨排出至體外,而保護中樞神經系統以外,尚具有促進能量代謝並促進疲勞恢復之效果。 In addition to improving liver function, lysine is also used as materials such as antibodies, hormones, and enzymes to repair body tissues. Histamine acts on the joints and exerts effects on prevention / improvement of chronic joint rheumatism. In addition to improving liver function, valine acid also strengthens the body's muscles or restores fatigue. In addition, threonine also improves liver function and functions as a nutrient that promotes growth. Tryptophan is a nerve-conducting substance in the brain and has the effect of stabilizing mental functions. Glutamate is contained in the liver or pork in large quantities and is quickly absorbed by the body as an energy source. Serine is contained in soybeans and has the effect of suppressing skin aging. In addition, asparagine and aspartic acid excrete ammonia that is a harmful substance to the body and protect the central nervous system. They also have the effects of promoting energy metabolism and promoting fatigue recovery.

圖12係顯示依據本實施例之發酵熟成胎盤溶液的固形份之礦物質/維生素含量。將未經發酵熟成之胎盤溶液的固形份作為比較例。 FIG. 12 shows the mineral / vitamin content of the solid content of the fermented and matured placenta solution according to this embodiment. The solid content of the placenta solution which was not fermented and matured was made into the comparative example.

在熟成步驟之後所計測之成分,在依據本實施例之發酵熟成胎盤溶液的固形份中,若與未經發酵熟成之胎盤溶液的固形份進行比較,則特定而言,鈉、鈣、鎂、菸鹼酸、鋅、維生素B1、維生素B2、維生素B6係大幅增加, 包含鈉300mg/100g以上、鈣100mg/100g以上、鎂15mg/100g以上、菸鹼酸2mg/100g以上、鋅2mg/100g以上、維生素B1 0.1mg/100g以上、維生素B2 0.1mg/100g以上、維生素B6 0.05mg/100g以上。 When the components measured after the maturation step are compared with the solid content of the fermented and matured placenta solution according to this example, compared with the solid content of the unfermented and matured placental solution, specifically, sodium, calcium, magnesium, Nicotinic acid, zinc, vitamin B 1 , vitamin B 2 , and vitamin B 6 have increased significantly, including 300mg / 100g or more sodium, 100mg / 100g or more calcium, 15mg / 100g or more magnesium, 2mg / 100g or more nicotinic acid, and 2mg zinc / 100 g or more, vitamin B 1 0.1 mg / 100 g or more, vitamin B 2 0.1 mg / 100 g or more, and vitamin B 6 0.05 mg / 100 g or more.

在SAMe之分析中,係使用薄層層析(TLC)及HPLC定量。 In the analysis of SAMe, thin layer chromatography (TLC) and HPLC were used for quantification.

在TLC之樣品調整中,係設為以1.5N鹽酸於室溫下萃取1小時。在展開溶媒中,係以4:1:2使用1-丁醇:醋酸:水,並以茚三酮顯色進行檢測。 In the TLC sample adjustment, extraction was performed with 1.5N hydrochloric acid at room temperature for 1 hour. In the developing solvent, 1-butanol: acetic acid: water was used at 4: 1: 2, and the color was detected by ninhydrin.

HPLC定量係使用「GL Sciences股份有限公司GL-7400型」機器,並使用管柱(Kemco股份有限公司Chemcopak Nucleosil 100-10SA),移動相係依流速1.0mL/分鐘,以利用0.05M(NH4)2HPO4(pH 3.0)20分鐘,接著以5分鐘使組成變化成0.5M(NH4)2HPO4(pH 3.0)之線性梯度實行,並於260nm進行檢測。分析方法係依據後藤等人之方法(參考出處:「清酒醪中之S-腺苷甲硫胺酸的定量及變化」日本釀造協會誌,1992)。 Quantitative HPLC system using "GL Sciences Co., Ltd. GL-7400 type" machine, and using the column (Kemco Co. Chemcopak Nucleosil 100-10SA), a flow rate of the mobile phase system by 1.0mL / min, to take advantage of 0.05M (NH 4 ) 2 HPO 4 (pH 3.0) for 20 minutes, followed by a 5 minute change in composition to a linear gradient of 0.5M (NH 4 ) 2 HPO 4 (pH 3.0), and detection was performed at 260 nm. The analysis method is based on the method of Goto et al. (Reference source: "Quantitative and change of S-adenosylmethionine in sake sake", Japan Brewing Association Journal, 1992).

在SA胺基酸之分析中係使用HPLC定量。 Quantification of SA amino acids was performed using HPLC.

使用「GL Sciences股份有限公司GL-7400型」機器,並使用管柱(GL Sciences股份有限公司Inertsil ODS-4),移動相係依流速1.0mL/分鐘,以甲醇:0.1%H3PO4=2:98實行,並於214nm進行檢測。分析方法係依據GL Sciences股份有限公司之分析應用程式(Data.No.LB110-0919)。 Using "GL Sciences Co., Ltd. GL-7400" machine, and using a column (GL Sciences Co., Ltd. Inertsil ODS-4), the mobile phase was at a flow rate of 1.0 mL / min, with methanol: 0.1% H 3 PO 4 = 2:98 implementation and detection at 214nm. The analysis method is based on the analysis application (Data. No. LB110-0919) of GL Sciences Corporation.

〔產業上之可利用性〕 [Industrial availability]

依據本發明之製造方法所製造之發酵熟成胎盤溶液係可利用為健康食品或化妝品用原料。 The fermented cooked placenta solution produced by the production method of the present invention can be used as a raw material for health food or cosmetics.

Claims (4)

一種發酵熟成胎盤溶液的製造方法,係在豬、羊或馬的胎盤溶液中,加入具有發酵作用之酵母菌而使前述胎盤發酵及熟成之發酵熟成胎盤溶液的製造方法,其特徵為具有下列步驟:將前述黑糖添加至前述胎盤溶液中之黑糖添加步驟;在前述黑糖添加步驟之後,於80~100℃的溫度中進行20分鐘~60分鐘加熱殺菌之殺菌步驟;在前述殺菌步驟之後,強制冷卻至35℃以下的溫度之冷卻步驟;在前述冷卻步驟之後,加入前述酵母菌並於20℃~35℃的溫度中使其發酵1個月之發酵步驟;以及在前述發酵步驟之後,於20℃~25℃的溫度中使其熟成2個月之熟成步驟,前述黑糖添加步驟中,僅在發酵開始時將相對於前述胎盤溶液而言以重量比計6~15%的黑糖添加至前述胎盤溶液中。A method for manufacturing a fermented and matured placenta solution, which is a method for manufacturing a fermented and matured placenta solution by adding a fermenting yeast to a placental solution of a pig, a sheep or a horse, which is characterized by the following steps: : The brown sugar adding step of adding the aforementioned brown sugar to the aforementioned placenta solution; after the aforementioned brown sugar adding step, performing a sterilization step of heating and sterilizing at a temperature of 80 to 100 ° C for 20 minutes to 60 minutes; after the foregoing sterilizing step, forced cooling A cooling step to a temperature below 35 ° C; a fermentation step of adding the aforementioned yeast and fermenting it at a temperature of 20 ° C to 35 ° C for one month after the foregoing cooling step; and a temperature of 20 ° C after the foregoing fermentation step A maturation step of maturing for 2 months at a temperature of ~ 25 ° C. In the aforementioned brown sugar adding step, only 6 to 15% by weight of brown sugar relative to the aforementioned placental solution is added to the aforementioned placental solution at the beginning of fermentation. in. 如請求項1之發酵熟成胎盤溶液的製造方法,其中,在前述熟成步驟之後的固形份中所計測之分子量分佈係就未滿200而言為10~20%、就1000~3000而言為30~40%、就3000~6000而言為20~25%,而剩餘部分與前述分子量分佈合計為100%。The method for producing a fermented and matured placenta solution according to claim 1, wherein the molecular weight distribution measured in the solid content after the aforementioned ripening step is 10 to 20% for a content less than 200 and 30 for a mass of 1,000 to 3000. ~ 40%, and from 20 to 25% in terms of 3000 to 6000, and the remainder is 100% in total with the aforementioned molecular weight distribution. 如請求項1之發酵熟成胎盤溶液的製造方法,其中,在前述熟成步驟之後的發酵熟成胎盤溶液的固形份中,係包含丙胺酸10莫耳%以上、胱胺酸0.4莫耳%以上。The method for producing a fermented and matured placenta solution according to claim 1, wherein the solid content of the fermented and matured placental solution after the aforementioned maturation step includes alanine 10 mol% or more and cystine 0.4 mol% or more. 如請求項1之發酵熟成胎盤溶液的製造方法,其中,在前述熟成步驟之後的發酵熟成胎盤溶液的固形份中,係包含鈉300mg/100g以上、鈣100mg/100g以上、鎂15mg/100g以上、菸鹼酸2mg/100g以上、鋅2mg/100g以上。The method for producing a fermented and matured placenta solution according to claim 1, wherein the solid content of the fermented and matured placental solution after the aforementioned maturation step includes 300 mg / 100 g or more of sodium, 100 mg / 100 g or more of calcium, 15 mg / 100 g or more of magnesium, Nicotinic acid is more than 2mg / 100g, zinc is more than 2mg / 100g.
TW104137012A 2015-03-11 2015-11-10 Manufacturing method of fermented matured placenta solution TWI633189B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015048056A JP6282243B2 (en) 2015-03-11 2015-03-11 Method for producing fermentation-aged placenta solution
JP2015-048056 2015-03-11

Publications (2)

Publication Number Publication Date
TW201632627A TW201632627A (en) 2016-09-16
TWI633189B true TWI633189B (en) 2018-08-21

Family

ID=56880421

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104137012A TWI633189B (en) 2015-03-11 2015-11-10 Manufacturing method of fermented matured placenta solution

Country Status (5)

Country Link
JP (1) JP6282243B2 (en)
KR (1) KR20170040311A (en)
CN (1) CN106488708B (en)
TW (1) TWI633189B (en)
WO (1) WO2016143357A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6213756B1 (en) * 2017-02-09 2017-10-18 有限会社ポークランド Method for producing placenta extract, method for producing placenta extract-containing powder, and method for producing processed food
JP6373444B1 (en) * 2017-05-10 2018-08-15 株式会社ホルス Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185242A (en) * 2003-12-26 2005-07-14 Takashi Kondo Placenta-containing health food product and method for producing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101132392B1 (en) * 2009-08-14 2012-04-03 (주)청룡수산 Fermented Placenta Compositin and Use Thereof
CN102327291B (en) * 2011-07-12 2013-02-13 湖州康海斯生物科技有限公司 Stock solution of sheep embryo and sheep placental peptide and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185242A (en) * 2003-12-26 2005-07-14 Takashi Kondo Placenta-containing health food product and method for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mitsu Y et al, Safety and toxicological evaluation of a novel, fermented, peptide-enriched, hydrolyzed swine placenta extract power., Toxicol Mech Methods. 2015 Jan; 25(1):13-20. doi:10.3109/15376516.2014.971139.Epub 2014 Oct 20. *

Also Published As

Publication number Publication date
TW201632627A (en) 2016-09-16
CN106488708B (en) 2019-10-01
KR20170040311A (en) 2017-04-12
WO2016143357A1 (en) 2016-09-15
JP6282243B2 (en) 2018-02-21
JP2016167982A (en) 2016-09-23
CN106488708A (en) 2017-03-08

Similar Documents

Publication Publication Date Title
JP5653759B2 (en) Skin aging inhibitory peptide
BR112013011894B1 (en) collagen hydrolyzate to use to improve the health of human skin, hair and / or nails
KR101980361B1 (en) Collagen hydrolysate having high concentration of collagen tripeptide and uses thereof
JP6969067B2 (en) Anti-inflammatory, anti-aging and whitening agents
JP2017202990A (en) Cosmetics and food and drink composition
JP2017114814A (en) Cosmetics
JP6482930B2 (en) Skin cosmetics and foods and drinks
TWI633189B (en) Manufacturing method of fermented matured placenta solution
JP6877924B2 (en) Epidermal cell-cell function enhancer
JP5025254B2 (en) Cosmetic preparations and cosmetics for improving the skin groove density
US20080153741A1 (en) Compounding ingredients for cosmetic formulation for improving skinditch density and cosmetic
JP6666650B2 (en) Skin cosmetics, hair cosmetics and foods and drinks
WO2006078067A1 (en) Age production inhibitor, use of the same, and process for production of the same
JP7082827B2 (en) Cosmetics
JP6122200B1 (en) Anti-glycation composition
JP2012041276A (en) Carbonylation inhibitor of protein, or transparency improver of skin
KR20070034212A (en) Health functional food for immune strengthening or antioxidant containing whey protein hydrolyzate as an active ingredient
Maeda Skin-moisturizing effect of collagen peptides taking orally
WO2009155097A1 (en) Natural product inhibitors of 3dg
JP6981685B2 (en) Skin cosmetics, hair cosmetics and food and drink
JP7111789B2 (en) Skin topical agent
JP6993627B2 (en) Skin cosmetics, hair cosmetics and food and drink
JP2012171909A (en) Glycation inhibitor
EP4046624A1 (en) Uses of white roselle extract for skin hydrating
WO2021205852A1 (en) Biological function regulating agent, epidermal metabolism promoting agent, fat accumulation inhibiting agent, fat decomposition promoting agent, adiponectin production promoting agent, functional food, cosmetic, and method for producing biological function regulating agent